Literature DB >> 32937181

Reassessment of minimal media reveals differences in growth among Porphyromonas gingivalis standard strains.

Keitarou Saiki1, Yumiko Urano-Tashiro2, Yukihiro Takahashi3.   

Abstract

OBJECTIVES: Porphyromonas gingivalis is one of the etiologic agents of chronic periodontitis. Our previous study showed that the use of minimal media for P. gingivalis allowed to isolate novel inhibitors of P. gingivalis growth. However, growth of P. gingivalis in minimal media was not always reproducible.
METHODS: To explain this phenomenon, we analyzed the growth of seven wild-type ATCC 33277 strains and two wild-type W83 strains in 10 minimal media and three complex media.
RESULTS: All nine strains grew in LF (Lactalbumin-Ferric chloride), GC (bovine γ-immunoglobulin G-Calcium chloride), and newly developed mC (milk-Casein) minimal media. Therefore, LF, GC, and mC could be used as minimal media for P. gingivalis. In contrast, other six minimal media containing bovine serum albumin (BSA) supported the growth of several less strains; among these, two media also showed lack of reproducibility in growth among ATCC 33277 strains. On the other hand, four ATCC 33277 strains grew similarly in all 13 media, but two W83 and other three ATCC 33277 strains grew differently in at least one medium.
CONCLUSIONS: These results suggest that the lack of reproducibility of P. gingivalis growth on minimal media is caused by the presence of BSA, and by differences among the standard strains of P. gingivalis.
Copyright © 2020 Japanese Association for Oral Biology. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  BSA; Menadione; Minimal medium; Porphyromonas gingivalis; Standard strain

Year:  2020        PMID: 32937181     DOI: 10.1016/j.job.2020.09.004

Source DB:  PubMed          Journal:  J Oral Biosci        ISSN: 1349-0079


  1 in total

1.  The Efficacy of Minocycline Hydrochloride Combined with Multiple Antibiotic Paste in Elderly Patients with Chronic Periodontitis and Concomitant Pulp Lesions.

Authors:  Qiang Chen; Wen Yan; Nan Geng
Journal:  Evid Based Complement Alternat Med       Date:  2022-07-04       Impact factor: 2.650

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.